US · guidance
CMS Pub. 100-04, ch. 7, § 100
Epoetin (EPO)
SNF-543
EPO is a biologically engineered protein which stimulates the bone marrow to make new
red blood cells. Patients with anemia associated with chronic renal failure include all
ESRD patients regardless of whether they are on dialysis.
EPO is covered for the treatment of anemia for patients with chronic renal failure who are
receiving dialysis when it is administered in a renal dialysis facility (RDF).
EPO is not included in SNF PPS and may be billed separately when given in conjunction
with dialysis by the Renal Dialysis Facility. It must be billed by the RDF.
EPO is not a SNF outpatient benefit.
History
(Rev. 1, 10-01-03)
Provenance
- Source
- cms.gov
- Retrieved
- 2026-08-25
- Edition
- iom-2026-08-25
- Content hash
0d0a995691cc074bf335c9bb8baada01c217ea8340d63630778f61d208759dd0
The link goes to the issuing authority’s own document — the one we read to produce this record. Where a source publishes whole titles rather than sections, your browser may need a moment to jump to the provision.
Unofficial copy of government-published law, reproduced from official sources with full provenance. Not an official publication; verify against official sources before relying on it in a filing. Records in the 'guidance' corpus, and only that corpus, are sub-regulatory (interpretive guidelines, survey procedures) and are not binding law. Validity bounds follow each jurisdiction's declared temporalBasis.